


**AMENDMENT TO THE CLAIMS**

Please amend the claims as follows:

1. (original) A conjugate having the following structure



wherein

R represents -N(CH<sub>2</sub>-)<sub>2</sub>, -NHCH<; or -NHCH(CH<sub>2</sub>-)<sub>2</sub>,

X represents a hydrogen or a peptidic group, and

L<sub>A</sub> is optionally present and is an amino acid or a peptide containing at least 2 amino acid residues,

L<sub>B</sub> is optionally present and is an amino acid or a peptide containing at least 2 amino acid residues,

P is a peptide selected from full length or fragments of amyloid proteins or proteins with substantial similarity to an amyloid protein,

Y is OH or NH<sub>2</sub>,

and pharmaceutically acceptable salts thereof.

2. (original) A conjugate according to claim 1, which upon administration to a mammal is capable of eliciting a production of antibodies having specificity towards the conjugate itself, and inducing an immune response in the mammal, thereby preventing or reducing amyloid- induced cellular toxicity and/or the formation of amyloid fibrils, plaques and/or deposits.

3. (original) A conjugate according to claim 2, wherein the antibodies produced are having specificity towards one or more C-terminally presented P peptides of the conjugate.

4. (currently amended) A conjugate according to ~~any of claims 1-3~~, wherein P is a fragment comprising at least one region of an amyloid protein.

5. (original) A conjugate according to claim 4, wherein the region is selected from the group comprising the C-terminal region, beta sheet region, cytotoxic region, GAG-binding site region, or macrophage adherence region.

6. (currently amended) A conjugate according to ~~any of the preceding claims~~ 1, wherein the amyloid proteins are derived from amyloid precursor proteins selected from the group comprising serum amyloid A protein (ApoSSA), immunoglobulin light chain, immunoglobulin heavy chain, ApoA1, transthyretin, lysozyme, fibrinogen alpha chain, gelsolin, cystatin C, amyloid beta protein precursor (beta.-APP), betas microglobulin, prion precursor protein (PrP), atrial natriuretic factor, keratin, islet amyloid polypeptide and synuclein or any polypeptides with substantial similarity to any of the above.

7. (currently amended) A conjugate according to ~~any of claims 1-5~~, wherein the amyloid proteins are selected from amyloid beta (1-43), amyloid beta (1- 42), amyloid beta (1-41), amyloid beta (1-40), amyloid beta (1-39) and amyloid beta (1-38).

8. (original) A conjugate according to claim 7, wherein P is a fragment of amyloid beta (1-43),

amyloid beta (1-42), amyloid beta (1-41), amyloid beta (1-40), amyloid beta (1-39) or amyloid beta (1-38).

9. (original) A conjugate according to claim 8, wherein P contains the C- terminus of amyloid beta.

10. (original) A conjugate according to claim 8, wherein P is a fragment of 10 amino acids from the C-terminus of amyloid beta.

11. (original) A conjugate according to claim 8, wherein P is a fragment of 9 amino acids from the C-terminus of amyloid beta.

12. (original) A conjugate according to claim 8, wherein P is a fragment of 8 amino acids from the C-terminus of amyloid beta.

13. (original) A conjugate according to claim 8, wherein P is a fragment of 7 amino acids from the C-terminus of amyloid beta.

14. (original) A conjugate according to claim 8, wherein P is a fragment of 6 amino acids from the C-terminus of amyloid beta.

15. (original) A conjugate according to claim 8, wherein P is a fragment of 5 amino acids from the C-terminus of amyloid beta.

16. (original) A conjugate according to claim 8, wherein P is a fragment of 4 amino acids from the C-terminus of amyloid beta.

17. (original) A conjugate according to claim 8, wherein P is a fragment of 3 amino acids from the C-terminus of amyloid beta.

18. (original) A conjugate according to claim 12, wherein P is fragment 35- 42 of amyloid beta (1- 42).

19. (original) A conjugate according to claim 13, wherein P is fragment 36- 42 of amyloid beta (1 42).

20. (original) A conjugate according to claim 14, wherein P is fragment 37- 42 of amyloid beta (1- 42).

21. (original) A conjugate according to claim 15, wherein P is fragment 38- 42 of amyloid beta (1- 42).

22. (original) A conjugate according to claim 16, wherein P is fragment 39- 42 of amyloid beta (1- 42).

23. (original) A conjugate according to claim 17, wherein P is fragment 40- 42 of amyloid beta

(1- 42).

24. (currently amended) A conjugate according to ~~any of the preceding claims~~ 1, wherein X is a T cell epitope.

25. (original) A conjugate according to claim 24, wherein X is a human T cell epitope including full-length tetanus toxoid, tetanus toxoid fragment FNNFTVSFWLRVPKVSASHLE and tetanus toxoid fragment YNDMFNNFTVSFWLRVPKVSASHLEQYGT, or a rodent T cell epitope including QYIKANSKFIGITEL.

26. (currently amended) A conjugate according to ~~any of claims 1-23~~, wherein X is Keyhole Limpet Hemocyanin or BSA.

27. (currently amended) A method for the treatment, amelioration and/or prophylaxis of an amyloid-related disease in a mammal, the method comprising administering to the mammal an antigenic amount of a conjugate as ~~defined~~ recited in ~~any of the claims 1-26~~, wherein the conjugate elicits the production of antibodies having specificity towards the conjugate itself and induces an immune response in the mammal, thereby preventing or reducing amyloid- induced cellular toxicity and/or the formation of fibrils, plaques and/or amyloid deposits.

28. (currently amended) A method according to claim 27, wherein the antibodies produced are ~~being~~ specific towards one or more C-terminally presented P peptides of ~~a~~ the conjugate ~~as defined in claims 1-26~~.

29. (currently amended) A method according to claim 27-~~or~~-28, the method further comprises the administration of an adjuvant together with the conjugate.

30. (original) A method according to claim 29, wherein the adjuvant is selected from the group comprising complete Freund's adjuvant, incomplete Freund's adjuvant, QS21, Aluminium hydroxide gel, MF59 and calcium phosphate.

31. (original) A method according to ~~any of~~ claims 27-30, wherein the amyloid- related disease is Alzheimer's disease, Down's syndrome, vascular dementia or cognitive impairment.

32. (currently amended) Use of a conjugate as defined in ~~any of~~ claims 1-26 for the preparation of a pharmaceutical composition for the treatment and/or prophylaxis of an amyloid-related disease in a mammal.

33. (currently amended) A vaccine comprising a conjugate as ~~defined~~-recited in claims 1-26 together with an adjuvant.

34. (original) A vaccine according to claim 33, wherein the adjuvant is selected from the group comprising complete Freund's adjuvant, incomplete Freund's adjuvant, QS21, Aluminium hydroxide gel, MF59 and calcium phosphate.

35. (currently amended) A method for producing an antibody in a mammal, the method comprising administering to the mammal an antigenic amount of a conjugate as ~~defined~~-recited

in ~~any of the~~ claims 1-26, wherein the conjugate elicits the production of antibodies having specificity towards the conjugate itself.

36. (currently amended) A method according to claim 35, wherein antibodies produced are ~~being~~ specific towards one or more C-terminally presented P peptides of athe conjugate ~~as defined in claims 1-26~~.

37. (currently amended) A method according to claim 35 ~~or 36~~, which further comprises the step of generating hybridoma cells by somatic cell hybridization for the production of monoclonal or polyclonal antibodies.

38. (currently amended) A method according to ~~any of~~ claims 35-37, wherein the mammal is a mouse or humanized mouse.

39. (currently amended) An antibody having specificity towards a conjugate as ~~defined~~ recited in claims 1-26.

40. (currently amended) An antibody as recited in claim 39, wherein the antibody is having specificity towards one or more C- terminally presented P peptides in a~~the~~ conjugate ~~as defined in any of claims 1-26~~.

41. (currently amended) An antibody according to claim 39 ~~or 40~~, which is monoclonal.

42. (currently amended) An antibody according to ~~any of claims 39-41~~, which is humanized or chimeric.

43. (currently amended) An antibody according to ~~any of claims 39-42~~, which is produced administering to a mammal an antigenic amount of the conjugate~~by a method as defined in claims 35-48~~.

44. (currently amended) A method for the treatment and/or prophylaxis of an amyloid- related disease in a mammal, the method comprising administering to the mammal an antibody as ~~defined~~ recited in claims 39-43, thereby preventing or reducing amyloid-induced cellular toxicity and/or the formation of fibrils, plaques and/or amyloid deposits.

45. (original) A method according to claim 44, wherein the amyloid-related disease is Alzheimer's disease, Down's syndrome, vascular dementia or cognitive impairment.